Literature DB >> 17097607

Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury.

Hui Yin1, Bao-Jun Huang, Heng Yang, Ya-Fei Huang, Ping Xiong, Fang Zheng, Xiao-Ping Chen, Yi-Fa Chen, Fei-Li Gong.   

Abstract

The interleukin-1 receptor-like protein ST2 exists in both membrane-bound (ST2L) and soluble form (sST2). ST2L has been found to play an important regulatory role in Th2-type immune response, but the function of soluble form of ST2 remains to be elucidated. In this study, we report the protective effect of soluble ST2 on warm hepatic ischemia/reperfusion injury. We constructed a eukaryotic expression plasmid, psST2-Fc, which expresses functional murine soluble ST2-human IgG1 Fc (sST2-Fc) fusion protein. The liver damage after ischemia/reperfusion was significantly attenuated by the expression of this plasmid in vivo. sST2-Fc remarkably inhibited the activation of Kupffer cells and the production of proinflammatory mediators TNF-alpha and IL-6. Furthermore, the levels of TLR4 mRNA and the nuclear translocation of NF-kappaB were also suppressed by pretreatment with sST2-Fc. These results thus identified soluble ST2 as a negative regulator in hepatic I/R injury, possibly via ST2-TLR4 pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097607     DOI: 10.1016/j.bbrc.2006.10.166

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Implications for Interleukin-33 in solid organ transplantation.

Authors:  Quan Liu; Hēth R Turnquist
Journal:  Cytokine       Date:  2013-03-27       Impact factor: 3.861

2.  Adenovirus-mediated overexpression of soluble ST2 provides a protective effect on lipopolysaccharide-induced acute lung injury in mice.

Authors:  H Yin; X Y Li; B H Yuan; B B Zhang; S L Hu; H B Gu; X B Jin; J Y Zhu
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

3.  High-mobility group box 1 exacerbates concanavalin A-induced hepatic injury in mice.

Authors:  Quan Gong; Hui Zhang; Jun-hua Li; Li-hua Duan; Shan Zhong; Xiao-ling Kong; Fang Zheng; Zheng Tan; Ping Xiong; Gang Chen; Min Fang; Fei-li Gong
Journal:  J Mol Med (Berl)       Date:  2010-09-17       Impact factor: 4.599

4.  Transforming growth factor-beta1 upregulates the expression of CXC chemokine receptor 4 (CXCR4) in human breast cancer MCF-7 cells.

Authors:  Xiao-ping Zhao; Yong-yao Huang; Yu Huang; Ping Lei; Ji-lin Peng; Sha Wu; Min Wang; Wen-han Li; Hui-fen Zhu; Guan-xin Shen
Journal:  Acta Pharmacol Sin       Date:  2010-02-15       Impact factor: 6.150

5.  Soluble ST2 plasma concentrations predict mortality in severe sepsis.

Authors:  Jacobien J Hoogerwerf; Michael W T Tanck; Marieke A D van Zoelen; Xavier Wittebole; Pierre-François Laterre; Tom van der Poll
Journal:  Intensive Care Med       Date:  2010-02-12       Impact factor: 17.440

6.  Blockade of IL-33 ameliorates Con A-induced hepatic injury by reducing NKT cell activation and IFN-γ production in mice.

Authors:  Jie Chen; Lihua Duan; Ali Xiong; Hongwei Zhang; Fang Zheng; Zheng Tan; Feili Gong; Min Fang
Journal:  J Mol Med (Berl)       Date:  2012-09-16       Impact factor: 4.599

Review 7.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

8.  Elevated levels of soluble ST2 protein in dengue virus infected patients.

Authors:  Aniuska Becerra; Rajas V Warke; Norma de Bosch; Alan L Rothman; Irene Bosch
Journal:  Cytokine       Date:  2008-01-28       Impact factor: 3.861

9.  Adenovirus-mediated delivery of soluble ST2 attenuates ovalbumin-induced allergic asthma in mice.

Authors:  H Yin; X Y Li; T Liu; B H Yuan; B B Zhang; S L Hu; H B Gu; X B Jin; J Y Zhu
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330

Review 10.  The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.

Authors:  Cem Gabay; Iain B McInnes
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.